Market Access Professionals in the Pharmaceutical Industry in the United Kingdom: Essential Roles, Knowledge, Skills, and Attributes

Clara T. Fatoye; Gillian  Yeowell; Eula Miller; Isaac Odeyemi; Chidozie Mbada

doi:10.20883/medical.e1341

Authors

Clara T. Fatoye Department of Health and Social Care, University Campus Oldham, Oldham, United Kingdom https://orcid.org/0000-0003-3509-5065
Gillian Yeowell Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom
Eula Miller School of Nursing and Public Health, Manchester Metropolitan University, Manchester, United Kingdom https://orcid.org/0000-0002-0609-2634
Isaac Odeyemi Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom https://orcid.org/0000-0002-9037-9290
Chidozie Mbada Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom https://orcid.org/0000-0003-3666-7432

DOI:

https://doi.org/10.20883/medical.e1341

Keywords:

market access, pharmaceutical industry, roles, skills, United Kingdom

Abstract

Introduction. Clearly defined roles and educational standards are crucial for enhancing professional status and facilitating Market Access (MA) in the pharmaceutical industry (pharma). However, literature on this topic remains limited. This study explored MA professionals' roles within pharma in the United Kingdom (UK), including the knowledge, skills, competence, and other attributes required.

Materials and methods. A document analysis of UK MA job advertisements from pharmaceutical companies, National Health Service websites, and Google search engine was undertaken between February and August 2019, and updated between 1st and 31st August 2023. Thematic content analysis was used to analyse the data.

Results. Eighty advertisements met the inclusion criteria, classified by seniority: entry-level (44%), senior level (15%), pricing and reimbursement (11%), and head/director positions (30%). Entry-level roles displayed the most variability in titles. A degree in a relevant field was required for 86% of these positions, dropping to 38% for senior MA roles. While skills and activities varied, a strong understanding of healthcare systems and excellent communication skills were essential across all positions. The core attributes of MA professionals in pharma were defined by three MA components: 'right roles' (job responsibilities), 'right people' (reputation and skills), and 'right reward' (wages and remuneration).

Conclusions. This study is the first document analysis of MA job roles in pharma, focusing on their conceptualisation and definition. MA is an emerging profession characterised by diverse roles, varying entry requirements, and the need for collaboration across healthcare systems. The findings indicate that MA in pharma is still in the early stages of professionalisation and needs further development. To advance this evolution, developing competency frameworks, standardising job roles, and guiding curriculum design are recommended.

Downloads

Download data is not yet available.

References

Jarosławski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res 2011;11:259. https://doi.org/10.1186/1472-6963-11-259.

Zheng C, Ha J, Hydery T, Westrich K. HTA51 Impact of ICER Assessments on Payer Decision Making in the United States. Value in Health 2023;26:S268. https://doi.org/10.1016/j.jval.2023.03.1480.

Pereira CSSM. Examining the Role of Market Access in the Pharmaceutical Industry: A Scoping Review of European Practices (Master's thesis, Universidade de Lisboa (Portugal)). 2023. Retrieved April 09 2025. https://repositorio.ulisboa.pt/bitstream/10451/64350/1/MICF_Carolina_Pereira.pdf.

Chaudhury H. Market Access focus: What does modern market access really mean? 2018. Retrieved February 20 2024, from https://pf-media.co.uk/in-depth/market-access-focus-what-does-modern-market-access-really-mean.

Chowhan SS. Pharma’s future in developing market: A look at market access, elements, and trends. Rabindra Bharati University Journal of Economics. 2024;8:122-130.

Gold M. Beyond coverage and supply: measuring access to healthcare in today's market. Health Serv Res. 1998 Aug;33(3 Pt 2):625-52; discussion 681-4. PMID: 9685110; PMCID: PMC1975648.

Kockaya G. Collaborative Approaches to Market Access: Working with Stakeholders. Health Policy. 2024. https://marketaccesstoday.com/collaborative-approaches-to-market-access-working-with-stakeholders.

Kumar A, Juluru K, Thimmaraju PK, Reddy J, Patil A. Pharmaceutical market access in emerging markets: concepts, components, and future. Journal of Market Access & Health Policy 2014;2:25302. https://doi.org/10.3402/jmahp.v2.25302.

Van Nooten F, Holmstrom S, Green J, Wiklund I, Odeyemi IAO, Wilcox TK. Health economics and outcomes research within drug development. Drug Discovery Today 2012;17:615–22. https://doi.org/10.1016/j.drudis.2012.01.021.

Scherer FM. Pricing, Profits, and Technological Progress in the Pharmaceutical Industry. Journal of Economic Perspectives 1993;7:97–115. https://doi.org/10.1257/jep.7.3.97.

Bowen GA. Document Analysis as a Qualitative Research Method. Qualitative Research Journal 2009;9:27–40. https://doi.org/10.3316/QRJ0902027.

O’Leary Z. The essential guide to doing your research project (2nd ed.). Thousand Oaks, CA: SAGE Publications, Inc. 2014.

[1] Fatoye C, Yeowell G, Miller E, Odeyemi I, Mbada C. Conceptualisation and Role of Market Access in Pharmaceutical Industry: A Scoping Review. JMAHP 2024;12:81–99. https://doi.org/10.3390/jmahp12020007.

Communication. How to get started in Market Access. 2024. https://www.rxcomms.com/learning/guide-to-getting-started-in-market-access#:~:text=The%20Market%20Access%20Specialist%20is,ensuring%20compliance%20with%20regulatory%20standards. Retrieved February 20 2024

Acquis. The Intersection of Pricing, Reimbursement, and Market Access Strategies. 2023. Retrieved November 11, 2023 from https://www.acquisconsulting.com/our-thinking/pricing-reimbursement-market-access-strategy.

[1] Bruni DS, Verona G. Dynamic Marketing Capabilities in Science-based Firms: an Exploratory Investigation of the Pharmaceutical Industry. British J of Management 2009;20. https://doi.org/10.1111/j.1467-8551.2008.00615.x.

Turner A. The professional status of community pharmacists: an exploration of the perceptions of community pharmacists and the general public (Doctoral dissertation, Aston University). 2017.

[1] Adams D, Miller BK. Professionalism in nursing behaviors of nurse practitioners. Journal of Professional Nursing 2001;17:203–10. https://doi.org/10.1053/jpnu.2001.25913.

Swisher LLD, and Page CG. Professionalism in physical therapy: History, practice, and development. Philadelphia: Elsevier, 2005, pp 23–44.

Currie G, Wild A, Lockett A. Contestation over a Profession's Memory: The UK Pharmacy Profession, 1880–1905. Journal of Management Studies. 2025; p 1-33.

[1] Koch MA. Pharmaceutical Market Access: current state of affairs and key challenges – results of the Market Access Launch Excellence Inventory (MALEI). Journal of Market Access & Health Policy 2015;3:29679. https://doi.org/10.3402/jmahp.v3.29679.

Garrison L, Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. JPM 2017;7:10. https://doi.org/10.3390/jpm7030010.

Berndt ER, and Newhouse JP. Pricing and reimbursement in US pharmaceutical markets (No. w16297). National Bureau of Economic Research. 2010. https://www.nber.org/system/files/working_papers/w16297/w16297.pdf.

IJzerman MJ, Steuten LMG. Early Assessment of Medical Technologies to Inform Product Development and Market Access: A Review of Methods and Applications. Applied Health Economics and Health Policy 2011;9:331–47. https://doi.org/10.2165/11593380-000000000-00000.

Pauwels K, Huys I, Casteels M, Simoens S. Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs. Front Pharmacol 2016;7. https://doi.org/10.3389/fphar.2016.00144.

Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015 Sep 25;13:39. https://doi.org/10.1186/s12961-015-0028-5.

Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, Lim R, Longson C, Pezalla E, Salmonson T, Samaha D, Tunis S, Woodcock J, Hirsch G. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014 Nov;96(5):559-71. https://doi.org/10.1038/clpt.2014.145. Epub 2014 Jul 9.

Vallano A, Pontes C, Agustí A. The challenges of access to innovative medicines with limited evidence in the European Union. Front Pharmacol 2023;14:1215431. https://doi.org/10.3389/fphar.2023.1215431.

Fatoye C, Betts A, Odeyemi A, Fatoye F, Odeyemi I. PNS260 Problems Experienced By Involving Patients at Post-Launch STAGE of Pharmaceutical Product Development. Value in Health 2020;23:S684–5. https://doi.org/10.1016/j.jval.2020.08.1704.

Rabea M. Understanding the Factors that Impact the Pre-Launch Phase and New Product Launch Excellence in the Pharmaceutical Industry. AJIBM 2022;12:88–122. https://doi.org/10.4236/ajibm.2022.121007.

Mota RDO, Godinho Filho M, Ganga GMD, Da Silva JMN, Mendes GHDS. Assessing the drivers and capabilities for faster product launch: a scale for time‐to‐market reduction in start-ups. R&D Management 2025;55:127–64. https://doi.org/10.1111/radm.12688.

Facey KM, Rannanheimo P, Batchelor L, Borchardt M, De Cock J. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders. Int J Technol Assess Health Care 2020;36:459–68. https://doi.org/10.1017/S026646232000063X.

Ogayemi C, Filani OM, Osho GO. A Market Access Optimization Model for New Drug Indications in Emerging Pharmaceutical Markets. IJMRGE 2022;3:699–710. https://doi.org/10.54660/.IJMRGE.2022.3.3.699-710.

Dravida S, Dabral A, Sharma J. Chapter 4: Challenge in the use of real world evidence. In: Real-World Evidence in the Pharmaceutical Landscape. 2021. Gatekeeper Press.

Claire R, Elvidge J, Hanif S, Goovaerts H, Rijnbeek PR, Jónsson P, Facey K, Dawoud D. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop. Front Pharmacol 2024;14:1289365. https://doi.org/10.3389/fphar.2023.1289365.

Auwal FI, Clark EJ, Copeland CS, McClelland GR. From insight to impact: a qualitative study on pharmaceutical industry professionals’ perceptions of the value of patient engagement. Current Medical Research and Opinion 2025;41:1261–75. https://doi.org/10.1080/03007995.2025.2537888.

Pizzi LT, Onukwugha E, Corey R, Albarmawi H, Murray J. Competencies for Professionals in Health Economics and Outcomes Research: The ISPOR Health Economics and Outcomes Research Competencies Framework. Value in Health 2020;23:1120–7. https://doi.org/10.1016/j.jval.2020.04.1834.

Palatino V. How to get and develop a career in a market access role in the medical devices’ industry. In Career options in the pharmaceutical and biomedical industry: An insider’s guide, 2023; pp. 119-136.

Thomas JR. Job and Career Opportunities in the Pharmaceutical Industry: An Overview. In: Thomas JR, Saso L, Van Schravendijk C, editors. Career Options in the Pharmaceutical and Biomedical Industry, Cham: Springer International Publishing; 2023, p. 33–84. https://doi.org/10.1007/978-3-031-14911-5_3.

Hubbart JA. The Importance of Stakeholder Engagement Across Market Domains. J Glob Entrep Manage 2024;2:1–7. https://doi.org/10.59462/JGEM.2.1.106.

Umrania O, Jagtap NS. Optimising Pharmaceutical Sales and Marketing with Data Analytics. 2024 IEEE 3rd World Conference on Applied Intelligence and Computing (AIC), Gwalior, India: IEEE; 2024, p. 412–7. https://doi.org/10.1109/AIC61668.2024.10730850.

Rath B, and Kar SK. Real-World Data Analytics in Global Pharmaceutical Marketing. IUP Journal of Knowledge Management. 2016;14(2):48–59

Uzhakova (Née Sabirzyanova) N, Fischer S. Data-Driven Enterprise Architecture for Pharmaceutical R&D. Digital 2024;4:333–71. https://doi.org/10.3390/digital4020017.

Holmér GW, and Gamage IH. Development of a data-driven marketing strategy for an online pharmacy. 2022; Master Thesis. https://www.diva-portal.org/smash/get/diva2:1682303/FULLTEXT01.pdf

Kumar SA, Ananda Kumar TD, Beeraka NM, Pujar GV, Singh M, Narayana Akshatha HS, Bhagyalalitha M. Machine Learning and Deep Learning in Data-Driven Decision Making of Drug Discovery and Challenges in High-Quality Data Acquisition in the Pharmaceutical Industry. Future Med Chem 2022;14:245–70. https://doi.org/10.4155/fmc-2021-0243.

Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju P. Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe. JPM 2015;5:213–28. https://doi.org/10.3390/jpm5020213.

Olson DW. Market testing and postlaunch evaluation for consumer goods. The PDMA Handbook of New Product Development, 2007; pp.479-496.

Du Plessis D, Sake J-K, Halling K, Morgan J, Georgieva A, Bertelsen N. Patient Centricity and Pharmaceutical Companies: Is It Feasible? Ther Innov Regul Sci 2017;51:460–7. https://doi.org/10.1177/2168479017696268.

Zou KH, Salem LA, Ray A. Real-World Evidence in a Patient-Centric Digital Era. 1st ed. New York: Chapman and Hall/CRC; 2022. https://doi.org/10.1201/9781003017523.

Saini JPS, Thakur A, Yadav D. AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations. RSC Pharm 2025;2:437–54. https://doi.org/10.1039/D4PM00323C.

Shraddha Dingre, Vishal Girbane, Sujit Garudkar, Priyanka Todakari, Dhanashri Borawake, Meera Deshmukh. Integrating artificial intelligence in pharmaceutical marketing: Enhancing engagement and efficiency. World J Adv Eng Technol Sci 2025;15:526–39. https://doi.org/10.30574/wjaets.2025.15.3.0948.

Jen M-H, Mt-Isa S, Chu H, Bridges I, Cai Z, Dunger-Baldauf C, Guan J, Ma J, Ren M, Wang Z, He W. The Current Landscape of HTA Framework and Key Challenges. Statistics in Biopharmaceutical Research 2025:1–15. https://doi.org/10.1080/19466315.2025.2495307.

Ströhmer N. The Role of Real-World Evidence in Health Technology Assessment Decision-Making: Methodological Challenges and Recommendations From International Health Systems (Master's thesis, Universidade NOVA de Lisboa (Portugal)). 2024.

Schweitzer SO, Lu ZJ. Pharmaceutical Economics and Policy. vol. 1. Oxford University Press; 2018. https://doi.org/10.1093/oso/9780190623784.001.0001.

Runfola A, Guercini S, Milanesi M. Network interactions for pharmaceutical market access: findings from an explorative research. JBIM 2021;36:174–86. https://doi.org/10.1108/JBIM-07-2020-0371.

Sendyona S, Odeyemi I, Maman K. Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. Journal of Market Access & Health Policy 2016;4:31660. https://doi.org/10.3402/jmahp.v4.31660.

Guercini S, Milanesi M, Runfola A. Bridges to sustainable health systems: public-private interaction for market access. JBIM 2020;35:1929–39. https://doi.org/10.1108/JBIM-11-2019-0475.

De Cosmo LM. The Strategic Role of Sales Management for Market Access in the Pharmaceutical Sector. ESJ 2018;14. https://doi.org/10.19044/esj.2018.v14n34p146.

Malviya N, Malviya S, Dhere M. Transformation of Pharma Curriculum as Per the Anticipation of Pharma Industries-Need to Empower Fresh Breeds with Globally Accepted Pharma Syllabus, Soft Skills, AI and Hands-on Training. Ind J Pharm Edu Res 2023;57:320–8. https://doi.org/10.5530/ijper.57.2.41.

Conley SN, Foley RW, Gorman ME, Denham J, Coleman K. Acquisition of T-shaped expertise: an exploratory study. Social Epistemology 2017;31:165–83. https://doi.org/10.1080/02691728.2016.1249435.

Hansen, M. T. T-shaped stars: The backbone of IDEO’s collaborative culture. Interview with IDEO CEO Tim Brown. Chief Executive. https://chiefexecutive.net/ideo-ceo-tim-brown-t-shaped-stars-the-backbone-of-ideoaes-collaborative-culture__trashed. 2010, January 21.

Batt AM, Tavares W, Williams B. The development of competency frameworks in healthcare professions: a scoping review. Adv in Health Sci Educ 2020;25:913–87. https://doi.org/10.1007/s10459-019-09946-w.

Fallis D, Irwin S, Cervero R, Durning S. Frameworks to Guide Faculty Development for Health Professions Education: A Scoping Review. J Contin Educ Health Prof 2022;42:180–9. https://doi.org/10.1097/CEH.0000000000000376.

Randolph DS. Predicting the effect of extrinsic and intrinsic job satisfaction factors on recruitment and retention of rehabilitation professionals. J Healthc Manag. 2005 Jan-Feb;50(1):49-60; discussion 60. PMID: 15729907.

Atif A, Kashif Ur Rehman, Ijaz Ur Rehman, Muhammad AK, Asad AH. Impact of organizational commitment on job satisfaction and employee retention in pharmaceutical industry. Afr J Bus Manage 2011;5:7316–24. https://doi.org/10.5897/AJBM10.1296.

Alam SMdT. Factors Affecting Job Satisfaction, Motivation and Turnover Rate of Medical Promotion Officer (MPO) in Pharmaceutical Industry: A Study Based in Khulna City. Asian Bus Rev 2012;1:126–31. https://doi.org/10.18034/abr.v1i2.131.